Double-blind Randomized Parallel Arm Study of 3 Anti CD20 Monoclonal Antibodies in Patients with Moderate to Severe, Seropositive Rheumatoid Arthritis Inadequately Responding to Methotrexate Based Therapy. Efficacy Safety & Immunogenicity Results

被引：0
|
作者：
Haridas, Vikram [1 ]
Katta, Rahul [2 ,3 ]
Nalawade, Ajit [4 ]
Kharkar, Sandeep [5 ]
Zhdan, Vyacheslav [6 ]
Garmish, Olena [7 ]
Lopez-Lazaro, Luis [8 ]
Batra, Sonica [9 ]
Kankanwadi, Suresh [10 ]
机构：
[1] Sushruta Multispecial Hosp, Hubballi, Karnataka, India
[2] Katta Hosp, Jaipur, Rajasthan, India
[3] SR Kalla Mem Gen Hosp, Jaipur, Rajasthan, India
[4] Inamdar Multispecialty Hosp, Pune, Maharashtra, India
[5] CARE Hosp, Nagpur, Maharashtra, India
[6] MV Sklifosovskyi Poltava Reg Clin Hosp, Ukrainian Med Stomatol Acad, Higher State Educ Inst Ukraine, Dept Rheumatol, Poltava, Ukraine
[7] NAMSU, SI NS MD Strazhesko Inst Cardiol, Kiev, Ukraine
[8] Dr Reddys Labs SA, Basel, Switzerland
[9] Dr Reddys Labs Ltd, Bachupally, Telangana, India
[10] Dr Reddys Labs EU Ltd, Cambridge, England
来源：
JOURNAL OF RHEUMATOLOGY | 2018年 / 45卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
224
引用
收藏
页码：1052 / 1052
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy Results of a Phase 2, Double-Blind, Placebo-Controlled Clinical Study of Duvelisib with Background Methotrexate (MTX) in Adults with Moderate-to-Severe Rheumatoid Arthritis (RA)
    Leff, Richard
    Kumar, Sunil
    Nikulenkova, Natalia
    Kaidashev, Igor
    Allen, Kerstin
    Dunbar, Joi
    Stern, Howard
    Adams, Julian
    Weinblatt, Michael
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [22] Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate
    Matsuno, Hiroaki
    Tomomitsu, Masato
    Hagino, Atsushi
    Shin, Seonghye
    Lee, Jiyoon
    Song, Yeong Wook
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (04) : 488 - 494
  • [23] Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
    Gerd Burmester
    Edit Drescher
    Pawel Hrycaj
    David Chien
    Zhiying Pan
    Stanley Cohen
    Clinical Rheumatology, 2020, 39 : 3341 - 3352
  • [24] Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
    Gerd, Burmester
    Edit, Drescher
    Pawel, Hrycaj
    David, Chien
    Pan Zhiying
    Stanley, Cohen
    CLINICAL RHEUMATOLOGY, 2020, 39 (11) : 3341 - 3352
  • [25] Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study
    Krupashankar, D. S.
    Dogra, Sunil
    Kura, Mahendra
    Saraswat, Abir
    Budamakuntla, Leelavathy
    Sumathy, T. K.
    Shah, Radha
    Gopal, M. G.
    Rao, T. Narayana
    Srinivas, C. R.
    Bhat, Ramesh
    Shetty, Narendra
    Manmohan, G.
    Krishna, Kotla Sai
    Padmaja, Dalavoi
    Pratap, Dasiga Venkata Subrahmanya
    Garg, Vijay
    Gupta, Sandesh
    Pandey, Neeraj
    Khopkar, Uday
    Montero, Enrique
    Ramakrishnan, M. S.
    Nair, Pradip
    Ganapathi, Prasanna C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (03) : 484 - 492
  • [26] Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study
    Vikram Muralidhar Haridas
    Rahul Katta
    Ajit Nalawade
    Sandeep Kharkar
    Vyacheslav Zhdan
    Olena Garmish
    Luis Lopez-Lazaro
    Sonica Sachdeva Batra
    Suresh Kankanwadi
    BioDrugs, 2020, 34 : 183 - 196
  • [27] Efficacy and Safety Of Subcutaneous Administration Of Tabalumab, An Anti-B Cell Activating Factor Monoclonal Antibody, In Rheumatoid Arthritis: Results From a Phase 3 Multicenter, Randomized, Double-Blind Study
    Genovese, Mark C.
    Silverman, Gregg J.
    Emery, Paul
    Gupta, Ramesh
    Gill, Anne
    Komocsar, Wendy J.
    Veenhuizen, Melissa
    Xie, Li
    Berclaz, Pierre-Yves
    Lee, Chin
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S733 - S734
  • [28] Safety and Efficacy of Various Dosages of Ocrelizumab in Japanese Patients with Rheumatoid Arthritis with an Inadequate Response to Methotrexate Therapy: A Placebo-controlled Double-blind Parallel-group Study
    Harigai, Masayoshi
    Tanaka, Yoshiya
    Maisawa, Shingo
    JOURNAL OF RHEUMATOLOGY, 2012, 39 (03) : 486 - 495
  • [29] Efficacy and Safety of Mepolizumab as an Add-on Therapy in Chinese Patients With Severe Eosinophilic Asthma: A Randomized, Double-Blind, Parallel Group Phase 3 Study
    Chen, R.
    Wei, L.
    Dai, Y.
    Wang, Z.
    Yang, D.
    Jin, M.
    Xiong, C.
    Li, T.
    Hu, S.
    Song, J.
    Day, N.
    Chan, R.
    Zhong, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [30] Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study
    Yang, Yue
    Li, Jingyang
    Liu, Ju
    Liu, Lin
    Wang, Yongfu
    Hu, Jiankang
    Li, Zhijun
    Gu, Jieruo
    Zhang, Xiao
    Xiao, Zhengyu
    Zheng, Junjie
    Liu, Lin
    Li, Zhanguo
    Wei, James Cheng-Chung
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 42
12345